News

Life sciences brands do not lack strategy. The execution gap opens when that strategy has to pass through creation, Medical, Legal and Regulatory (MLR) review, localization, adaptation, approval and deployment across markets and channels. Each hand-off can introduce delay, duplication and uncertainty. The result is familiar: teams repeat work, assets sit idle, local markets wait and investment is absorbed by rework rather than better engagement.

Governance should close that gap, not widen it. When policies, approved claims and decision rights sit outside day-to-day workflows, compliance becomes a late-stage checkpoint. When they are designed into the process from the beginning, governance can become an execution enabler. This helps teams identify issues earlier, reuse approved content with greater confidence and keep activation moving without lowering standards.

The audience is changing. Content operations must respond

This matters because HCP information gathering behavior is changing too. In a small proprietary HH Global panel, 10 of 19 HCPs mentioned actively using AI in their clinical workflow; Open Evidence and ChatGPT were specifically referenced, and AI use was the highest-frequency sub-code in the dataset. While this is not a representative prevalence measure, it does, however, signal that some HCPs are already incorporating AI-enabled tools into how they find and work with information.

For life sciences marketers, producing more content is not an adequate response. The commercial advantage lies in making current, relevant and compliant content easier to activate and adapt as audience needs change. Slow approvals, inconsistent claims or delayed localization are not only internal inefficiencies; they can reduce a brand’s ability to engage HCPs responsively across markets and channels.

Build quality and compliance in from day one

End-stage compliance often creates multiple revision cycles, wasted effort and greater regulatory risk. Involving MLR teams from the outset can prevent avoidable rework and support smoother approvals, including alignment with FDA requirements in the US market. However, early integration is difficult when responsibilities are fragmented across large internal teams and agency partners, while version control, rights management and localization are managed in separate systems.

The answer is not to weaken governance in pursuit of speed. It is to make governance continuous across the execution journey: brief, creation, review, localization, adaptation, approval, deployment, reuse and optimization. That gives stakeholders shared visibility of what has been approved, which rules apply and what needs human review before work moves forward.

A recent HH Global pilot shows what this can mean in practice. For a US-based life sciences client, MediaMagic reviewed print and digital assets, including websites and printed prescribing information. Within the pilot sample, it captured 100% of the errors and non-compliant issues in a single quality-assurance cycle, with nothing missed. Across the formats tested, the process reported a 93% time saving against the human editing workflow. Review speed increased by 35% and productivity by 30%, rising to approximately 40% for longer-format assets. These results demonstrate the potential to increase review capacity and improve turnaround times while maintaining accuracy.

AI should operationalize expertise, not replace judgement

AI can help make complex, approved expertise repeatable, searchable and available at scale. Purpose-built models can apply defined brand, therapy and regional rules, route content through the right workflow, extract metadata and flag exceptions. Used well, this can standardize repeatable checks, reduce subjective variation and preserve institutional knowledge when key specialists are unavailable.

But regulated marketing does not benefit from autonomous decision-making for its own sake. Human reviewers remain essential for context, interpretation and real-world judgement, particularly where claims, evidence and risk are nuanced. The strongest operating model gives machines the repeatable work and people the consequential decisions. AI becomes a safety layer and an execution aid, not a substitute for accountable expertise.

From policy to activation: Governance in the workflow

HH Global’s perspective is grounded in execution. A consultancy may advise on governance, an agency may create compliant assets and a technology platform may automate individual steps. But HH Global connects life sciences expertise, workflow design, technology and activation capability across the content supply chain—helping approved strategy survive the journey into market.

Solutions, developed by Northell and HH Global, is proof of that end-to-end capability. Embedded within collaborative workflows, it brings project information into a shared source of truth and supports consistent reviews across print, digital, social, motion graphics and congress materials. Customizable rules can reflect brand, therapy and regional requirements, while real-time checks, alerts and audit trails improve visibility for creative teams, brand stakeholders and approvers.

AI “sidekicks” automate defined tasks such as ingesting assets, extracting metadata, verifying approvals and applying repeatable checks. Searchable content, approved terminology and rich metadata can also support modular reuse. The value is not the volume of features. It is the operating principle they demonstrate: governance embedded where work happens, with transparent human oversight and an auditable record of decisions.

Trust must be designed in as these capabilities expand. Recording content origins, tracking edits, adding watermarks and controlling image libraries or prompts can help brands protect authenticity and uphold ethical and brand standards. These controls matter because faster activation is only valuable when teams can understand how an output was created, which rules were applied and where human accountability sits.

Smarter content operations create the advantage

Competitive differentiation will not come from producing more content. It will come from building smarter, agile and compliant content operations. As Neil Evans argues, “brands need to operationalize governance through automation, enable modular content for faster deployment, use performance data as feedback and invest in change management so teams can adopt new ways of working.”

Done well, this model can reduce avoidable rework, make cycle times more predictable, improve the reuse of approved modules and give local markets greater agility. It can also free experienced teams from chasing files, versions and routine checks so they can focus on higher-value decisions and more responsive HCP engagement. These are framed benefits; their scale will depend on the organization, workflow and implementation.

The leadership challenge is therefore bigger than choosing an AI tool. It is to redesign how governance and execution work together: defining which expertise should be encoded, which decisions require people, how local variation is controlled and how teams learn from each activation. Technology can accelerate the system, but operating discipline, domain expertise and change management determine whether it delivers value.

Close the execution gap

Compliance and creativity do not have to compete. When governance is connected to execution from the start, it can provide the control that makes faster, more consistent activation possible. That is how life sciences organizations move beyond isolated automation and build content operations that are ready for changing channels, markets and HCP behaviors.

Explore how HH Global helps life sciences teams embed governance into execution, accelerating compliant content from approved strategy to responsive activation at scale.